Is Novartis a Buy?
Pharmaceutical giant Novartis (NYSE: NVS) has seen a strong performance so far in 2019. While the company has been outperformed by rivals like Amgen, Novartis has edged out over other competitors such as Johnson & Johnson.
However, some investors have started to worry that the company has been losing share in historically significant markets for the business. Specifically, Novartis has been a leader in the development of leukemia treatments, but its signature leukemia drug is losing market share at a significant rate. Coupled that with some recent scandals involving data manipulation on its newer, upcoming therapies, and it's not surprising that some investors are worried.
On the other hand, the company's top-performing drug in terms of sales revenue, Cosentyx, has been seeing drastic quarterly growth. Now that the company has announced positive results in a breast cancer trial, this could be the beginning of a significant upturn in growth for Novartis. While there's a lot to consider when looking at a company of this size, let's briefly gloss over some of the pros and cons surrounding the pharmaceutical giant right now and whether the stock is a buy.
Source Fool.com
